


## Supplemental information

**Supplemental Table. Grade ≥3 treatment-emergent adverse events occurring in ≥5% of patients by renal impairment subgroup\***

	CrCL ≥15 to <50 mL/min		CrCL 50 to <80 mL/min		CrCL ≥80 mL/min	
	Kd56 (n = 85)	Vd (n = 97)	Kd56 (n = 186)	Vd (n = 174)	Kd56 (n = 192)	Vd (n = 185)
Number of patients reporting TEAEs, n (%)	74 (87.1)	77 (79.4)	157 (84.4)	125 (71.8)	148 (77.1)	122 (65.9)
Anemia	28 (32.9)	12 (12.4)	29 (15.6)	17 (9.8)	23 (12.0)	17 (9.2)
Pneumonia	10 (11.8)	11 (11.3)	23 (12.4)	16 (9.2)	20 (10.4)	15 (8.1)
Hypertension	12 (14.1)	3 (3.1)	27 (14.5)	7 (4.0)	30 (15.6)	5 (2.7)
Thrombocytopenia	11 (12.9)	10 (10.3)	16 (8.6)	20 (11.5)	14 (7.3)	13 (7.0)
Fatigue	8 (9.4)	8 (8.2)	14 (7.5)	10 (5.7)	10 (5.2)	17 (9.2)
Diarrhea	3 (3.5)	6 (6.2)	6 (3.2)	17 (9.8)	10 (5.2)	17 (9.2)
Platelet count decreased	7 (8.2)	6 (6.2)	2 (1.1)	9 (5.2)	10 (5.2)	9 (4.9)
Dyspnea	8 (9.4)	2 (2.1)	12 (6.5)	2 (1.1)	9 (4.7)	6 (3.2)
Hyperglycemia	3 (3.5)	8 (8.2)	8 (4.3)	1 (0.6)	11 (5.7)	8 (4.3)
Lymphocyte count decreased	6 (7.1)	3 (3.1)	13 (7.0)	3 (1.7)	10 (5.2)	3 (1.6)
Asthenia	4 (4.7)	1 (1.0)	10 (5.4)	6 (3.4)	8 (4.2)	7 (3.8)
Lymphopenia	5 (5.9)	4 (4.1)	13 (7.0)	5 (2.9)	4 (2.1)	5 (2.7)
Peripheral neuropathy	0	4 (4.1)	5 (2.7)	16 (9.2)	1 (0.5)	8 (4.3)
Bronchitis	0	1 (1.0)	10 (5.4)	3 (1.7)	4 (2.1)	0
Hyponatremia	6 (7.1)	2 (2.1)	4 (2.2)	2 (1.1)	2 (1.0)	2 (1.1)
Pyrexia	5 (5.9)	0	4 (2.2)	2 (1.1)	5 (2.6)	1 (0.5)
Urinary tract infection	5 (5.9)	2 (2.1)	5 (2.7)	0	2 (1.0)	1 (0.5)
Syncope	0	2 (2.1)	1 (0.5)	9 (5.2)	1 (0.5)	1 (0.5)
Renal impairment	4 (4.7)	6 (6.2)	0	1 (0.6)	0	0
Hyperkalemia	6 (7.1)	2 (2.1)	1 (0.5)	1 (0.6)	0	0

\*Preferred term.

**Supplemental Figure S1. Trial profile.\***



\*The trial profile for the ENDEAVOR intent-to-treat population has been previously published.<sup>1</sup>

# Supplemental Figure S2. Summary of ENDEAVOR renal impairment subgroup study design and results

